Status: Recruiting
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
The primary purposes of this study are to determine the safety and tolerability of PQ203 in patients with advanced solid tumors including triple negative breast cancer (TNBC), and to determine a recommended Phase 2 dose level for future studies in TNBC.
Participants needed: 80
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: ProteinQure Inc.Updated: Feb 23, 2026Locations: 4
Eligibility criteria
At least 18 years old [+15]
Patients with primary central nervous system (CNS) malignancies (Patients with s... [+18]